Sartorius Stedim North America Spring Show Guide - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sartorius Stedim North America Spring Show Guide


Sartorius is an internationally leading bioprocess and laboratory technology provider specializing in the design, manufacture, and service of integrated solutions covering fermentation, filtration, purification, fluid management and laboratory technologies. Re-usable and single-use bioreactors, microbial fermentors, filtration devices, integrity testers, housings, comprehensive single-use fluid handling, storage and mixing technologies, cell culture media, validation, training services & support are also provided across the company’s portfolio. "Turning science into solutions" is our primary focus.

E-mail: Maritza.ramirez@sartorius.com

Website: www.sartorius.us

Shows attending:

  • PDA — booth 501
  • INTERPHEX — booth 3115

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here